Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

NCT01410331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia

Interventions

BIOLOGICAL: JVS-100(4 mg) or placebo/8 injections
BIOLOGICAL: JVS-100(8 mg) or placebo/8 injections
BIOLOGICAL: JVS-100(8 mg) or placebo/16 injections
BIOLOGICAL: JVS-100(16 mg) or placebo/16 injections

Sponsor

Juventas Therapeutics, Inc.